Skip to main content
HR 6717 115th Congress House

Depression Side Effect Labeling Awareness Act of 2018

Official title: To amend the Federal Food, Drug, and Cosmetic Act to require that the label of drugs with an increased risk of suicide or depression present such increased risk prominently, and for other purposes.

Introduced: September 6, 2018 See on congress.gov
Health Administrative law and regulatory proceduresConsumer affairsDepartment of Health and Human ServicesDrug safety, medical device, and laboratory regulation
More subjectsShow fewer subjects
Food and Drug Administration (FDA)Mental health
Sign in to write a letter Sign in to watch
This bill died when the 115th Congress ended
It never became law before the 115th Congress (2017–2018) adjourned, and bills don't carry over to the next Congress. It would have to be reintroduced. You can still save it for reference, but it won't receive updates.
 Everywhere this bill has been 2 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Sep 6, 2018
Referred to the House Committee on Energy and Commerce.
Sep 6, 2018
Introduced in House
 Ask about this bill AI · grounded in the bill text

Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.

AI answers can be imperfect; always confirm against the full bill text.

 Latest action September 6, 2018

Referred to the House Committee on Energy and Commerce.

 Plain-English summary Congressional Research Service

Depression Side Effect Labeling Awareness Act of 2018

This bill amends the Federal Food, Drug, and Cosmetic Act to require the label of a drug that has an increased risk of suicide or depression to prominently display such risk.

 Related & companion bills 1
  • HR 4404 Reintroduced Bill Depression Side Effect Labeling Awareness Act of 2019
 Bill text 1 version

Source documents hosted by congress.gov.

 Committees of jurisdiction 1
Cite this page click to expand
APA
U.S. Congress. (2026). H.R. 6717: Depression Side Effect Labeling Awareness Act of 2018. 115th Congress. Open America. https://openamerica.io/bill/115-HR-6717/
MLA
"H.R. 6717: Depression Side Effect Labeling Awareness Act of 2018." 115th Congress, 2026, Open America, https://openamerica.io/bill/115-HR-6717/.
Bluebook (legal)
H.R. 6717, 115th Cong. (2026), https://openamerica.io/bill/115-HR-6717/.
Markdown link
[H.R. 6717: Depression Side Effect Labeling Awareness Act of 2018](https://openamerica.io/bill/115-HR-6717/)
Report a problem